单次给药主要研究目的：考察中国健康受试者在空腹条件下，单次口服不同剂量水平的醋酸艾司利卡西平片的药代动力学（Pharmacokinetics, PK）特征和PK种族敏感性。多次给药主要研究目的：考察中国健康受试者在空腹条件下，多次口服同一剂量的醋酸艾司利卡西平片的药代动力学（Pharmacokinetics, PK）特征。

[Translation]

The main purpose of single-dose administration is to investigate the pharmacokinetic (PK) characteristics and PK ethnic sensitivity of eslicarbazepine acetate tablets at different dose levels in Chinese healthy subjects under fasting conditions. The main purpose of multiple-dose administration is to investigate the pharmacokinetic (PK) characteristics of eslicarbazepine acetate tablets at the same dose in Chinese healthy subjects under fasting conditions.

Start Date24 Sep 2024

Sponsor / Collaborator

Shanghai Shangyao Chinese-Western Pharmaceutical Co., Ltd

[+1]

CTR20220017

/ CompletedPhase 3

一项多中心、随机、双盲、安慰剂对照短期研究及为期一年的开放性、非对照安全扩展研究，评价醋酸艾司利卡西平片用于成人局灶起源癫痫伴有或不伴有局灶进展为双侧强直阵挛发作添加治疗的有效性和安全性以及长期疗效和安全性

[Translation] A multicenter, randomized, double-blind, placebo-controlled short-term study and a one-year open-label, non-controlled safety extension study to evaluate the efficacy and safety of eslicarbazepine acetate tablets as add-on treatment for adults with focal epilepsy with or without focal progression to bilateral tonic-clonic seizures, as well as long-term efficacy and safety

评价醋酸艾司利卡西平片用于成人局灶起源癫痫伴有或不伴有局灶进展为双侧强直阵挛发作添加治疗的疗效。

[Translation]

To evaluate the efficacy of eslicarbazepine acetate tablets as add-on treatment for adults with epilepsy of focal origin with or without focal progression to bilateral tonic-clonic seizures.

Start Date28 Jul 2022

Sponsor / Collaborator

Shanghai ZhongXi Pharmaceutical Co. Ltd.

[+1]

CTR20201102

/ CompletedNot Applicable

醋酸艾司利卡西平片在健康受试者中随机、开放、两周期、双交叉空腹和餐后状态下的生物等效性试验

[Translation] A randomized, open-label, two-period, double-crossover bioequivalence study of eslicarbazepine acetate tablets in healthy subjects under fasting and fed conditions

研究空腹或餐后状态下，单次口服醋酸艾司利卡西平片受试制剂(规格：400mg，生产商：扬子江药业集团有限公司，提供商：扬子江药业集团北京海燕药业有限公司）与参比制剂（Aptiom®，规格：400mg，持证商：Sunovion Pharmaceuticals Inc. ）在健康受试者体内的药代动力学行为，评价两种制剂的生物等效性。观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

To study the pharmacokinetic behavior of the test preparation of eslicarbazepine acetate tablets (specification: 400 mg, manufacturer: Yangtze River Pharmaceutical Group Co., Ltd., provider: Yangtze River Pharmaceutical Group Beijing Haiyan Pharmaceutical Co., Ltd.) and the reference preparation (Aptiom®, specification: 400 mg, licensee: Sunovion Pharmaceuticals Inc.) in healthy subjects after a single oral administration in the fasting or postprandial state, and to evaluate the bioequivalence of the two preparations. To observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date08 Jun 2020

Sponsor / Collaborator

Yangtze River Pharmaceutical Group Beijing Haiyan Pharmaceutical Co., Ltd.

100 Clinical Results associated with Eslicarbazepine Acetate

100 Translational Medicine associated with Eslicarbazepine Acetate

100 Patents (Medical) associated with Eslicarbazepine Acetate

633

Literatures (Medical) associated with Eslicarbazepine Acetate

01 Aug 2026·SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Pregnancy outcomes following Eslicarbazepine acetate exposure in women with epilepsy: A global safety database analysis from clinical development to 16 years of post-marketing experience

Article

Author: Di Foggia, Valentina ; Holenz, Joerg ; Gama, Helena ; Meneses, Carlos ; Lopes, Diogo ; Sousa, Carolina

PURPOSE:

Continuous collection of comprehensive data on women with epilepsy and their antiseizure medication use is essential, since current knowledge of associated risks remains limited. Our previous analysis (Costa et al. 2018) indicated that available data on the use of eslicarbazepine acetate (ESL) were insufficient to support definitive conclusions in pregnant women. To address this limitation, we have continued to systematically collect and evaluate pregnancy exposure and outcomes, with the objective of refining the understanding of ESL safety during pregnancy as additional evidence has accrued.

METHODS:

Pregnancy cases involving exposure to eslicarbazepine acetate were identified through a review of ESL exposure from the global safety database (including post-marketing and clinical trials cases), cumulatively up to September 30th, 2025, supplemented by searches of the EMBASE™ and MEDLINE® databases for relevant literature published between May 1st, 2009 (launch date) and September 30th, 2025.

RESULTS:

Overall, 159 notifications of pregnancy with ESL exposure were included in this analysis, 91 with known outcomes: 51 normal live births (56%, 51/91), 13 termination of pregnancies (14%, 13/91) and 27 with adverse outcomes (30%, 27/91); these including 13 miscarriages, 8 cases of congenital anomalies, 4 cases of neonate adverse effects and two premature birth. In 16 of these 27 pregnancies with adverse outcomes, ESL was used as add-on therapy to other ASMs, rather than as monotherapy. The literature review did not identify additional relevant information.

CONCLUSIONS:

Across all years with ESL exposure, no consistent pattern of congenital disorders or miscarriages was observed in pregnant women with epilepsy. While large safety databases support signal detection, there remains a need for high‑quality, adequately powered observational studies and continued pharmacovigilance to guide informed clinical decision‑making in this vulnerable population.

01 Jul 2026·BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Review

Author: Davies, Helen ; O'Neill, Francis ; Kyaw, Shwe Sin ; Groves, Alice ; Curley, Natalie ; Hughes, Dyfrig A. ; Bramon, Elvira ; Cross, Helen ; Curran, Sarah ; Mensah, Seth ; Swan, Jill ; Sargison, Jane ; Hayward, Judith ; Sisodiya, Sanjay M. ; Evans, William ; McLellan, Ailsa ; Frank, Bernhard ; Pirmohamed, Munir ; Bass, Nicholas ; Marson, Anthony G. ; De Villiers, Jana ; Higham, Jon ; Dello Russo, Cinzia ; Galloway, Lucy ; Zakrewska, Joanna M.

Carbamazepine is licensed in the United Kingdom for the treatment of epilepsy, bipolar disorder and trigeminal neuralgia. The related compounds oxcarbazepine and eslicarbazepine are licensed for the treatment of epilepsy. These drugs can cause immune‐mediated hypersensitivity reactions, which typically affect the skin, and can be of variable severity. The liver and other organ systems can also be affected. The HLA alleles, HLA‐B*15:02 , HLA‐B*15:11 and HLA‐A*31:01 , are known predisposing factors for these hypersensitivity reactions. Any treatment‐naïve patient, regardless of ancestry or indication for treatment, who is about to be prescribed carbamazepine, oxcarbazepine or eslicarbazepine, or has been on these drugs for less than 3 months, should undergo pharmacogenetic testing to identify all clinically relevant HLA alleles to reduce the risk of hypersensitivity reactions. Carbamazepine, oxcarbazepine and eslicarbazepine should be avoided in HLA‐B*15:02 ‐positive patients. These drugs should also be avoided in patients positive for HLA‐A*31:01 or HLA‐B*15:11 if an alternative is possible. Where it is not possible to use an alternative, treatment should only be commenced after careful consideration of the benefits and risks, with increased monitoring and advising patients on appropriate action to take if a skin rash occurs. Our guideline is compatible with other international pharmacogenetics prescribing guidelines. This guideline is grounded in the latest evidence but cannot account for all individual factors relevant to patient care. Therefore, prescribers must conduct a thorough assessment of each patient's risk–benefit profile, ensuring that therapy is optimised to maximise benefits whilst minimising potential harms.

03 Jun 2026·Expert Opinion On Drug Safety

Updated insights on levetiracetam-associated severe cutaneous adverse reactions: a real-world pharmacovigilance analysis

Article

Author: Wu, Zhanshen ; Li, Yanyan ; Zhang, Xiangyu ; Zhao, Yang

BACKGROUND:

Previous studies have explored the association between levetiracetam (LEV) and severe cutaneous adverse reactions (SCARs). However, most investigations have relied on clinical trial data or case reports from individual medical centers. Consequently, the precise relationship between LEV and SCARs in real-world settings remains elusive.

RESEARCH DESIGN AND METHODS:

Data from the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases were analyzed, focusing on LEV-associated SCAR events utilizing disproportionality analysis methods.

RESULTS:

This study identified a significant correlation between LEV and SCARs (p < 0.05). However, combined analyses with other antiepileptic drugs revealed that the association of LEV with SCARs was comparatively weaker (p < 0.05). Univariate logistic regression analysis indicated that males, individuals aged 45 ~ 65 years, and combination therapy with eslicarbazepine, phenytoin, carbamazepine, and lamotrigine significantly increased the risk of developing SCARs (p < 0.05). Notably, SCARs were most likely to occur within the initial week of LEV treatment (39.39%).

CONCLUSIONS:

Despite certain limitations, this study offers updated insights into the association between LEV and SCARs. These findings underscore the significance of monitoring and actively managing LEV-associated SCARs to promote its safe and effective use.

News (Medical) associated with Eslicarbazepine Acetate

22 Oct 2025

·www.drugs.com

New Study Offers Hope for People With Drug-Resistant Epilepsy

WEDNESDAY, Oct. 22, 2025 — For the estimated one-third of people with focal epilepsy who don’t respond well to initial medications, new research offers significant reason for optimism. A study suggests that even those considered "treatment-resistant" may eventually see a substantial reduction in their seizures over time. Focal epilepsy , the most common form of the neurological disorder, occurs when nerve cells in one area of the brain fire off an excessive burst of electrical signals. These focal seizures can manifest as unusual behaviors, abnormal emotions or strange sensations. The new study, part of the international Human Epilepsy Project , tracked nearly 150 adults who were deemed treatment-resistant. In other words, they still had seizures despite having tried at least four different anti-seizure medications. Some participants also had implantable devices. The researchers monitored participants for up to three years. The results, published Oct. 20 in JAMA Neurology , showed a promising outcome: 68% of participants had a reduction in seizure frequency during the second half of the study compared to the first half. This finding directly contradicts the long-held assumption that the prospect for relief is remote when patients fail a handful of medications. “Our findings challenge the assumption that once a patient with focal epilepsy has failed a certain number of anti-seizure drugs, their chances of finding relief are small and not worth the effort,” said lead author Dr. Ojas Potnis, a neurology resident at the NYU Grossman School of Medicine in New York City. While medications rarely halted seizures completely, they did appear to lengthen the intervals between episodes for some patients, the study found. Almost 13% of volunteers went at least three months without a seizure. Almost 13% of volunteers went at least three months without a seizure. Nearly 8% were seizure-free for at least six months. Nearly 8% were seizure-free for at least six months. And 3% of patients achieved a full year or more without a seizure. And 3% of patients achieved a full year or more without a seizure. Potnis noted that these percentages, while appearing small, are higher than those found in earlier studies, which followed patients for just three months. This suggests that achieving seizure reduction is often a long game. The data also indicated that the total number of medications a patient had failed previously had no bearing on their future likelihood of improvement. The study noted that the four most common anti-seizure medications used by participants who experienced seizure reduction were all approved within the past 15 years. They are cenobamate , clobazam , eslicarbazepine and epidiolex . The researchers also found that whether or not patients had an implantable device had no effect on seizure trajectory. “These results offer hope that focal epilepsy will get better over time for most people,” said co-senior author Dr. Jacqueline French , a neurologist and professor at the NYU Grossman School of Medicine. “Health care providers should keep searching for the best treatment regimen for their patients no matter how many therapies they may need to try,” she added in a news release. The researchers said it remains unclear whether this gradual reduction in seizures is a result of therapeutic management — as more than half of those who improved started a new drug during the study — or the natural progression of disease over time. The study was funded by UCB, Neurelis and SK Life Science. Sources NYU Langone Health, news release, Oct. 20, 2025 JAMA Neurology, Oct. 20, 2025

Clinical Result

10 Jul 2023

·www.biospace.com

Sumitomo Pharma America Launches as New Combined Organization with Expanded Scale, Resources & Capabilities

CAMBRIDGE, Mass., July 10, 2023 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA), as previously announced on April 3, 2023, is pleased to share it has successfully launched its operations in the U.S. and related markets. The newly combined company is focused on addressing unmet patient needs in critical disease areas across psychiatry & neurology, oncology, urology, women's health, rare disease, and cell & gene therapies. SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets, with topline data for two of its Phase 3 candidates in the fields of psychiatry and urology expected this quarter. The company will apply its proprietary advanced analytics and computational technology platforms to support and accelerate its diverse pipeline and commercial programs as well as needed innovations in priority areas of discovery, science, research and development. SMPA's President and Chief Executive Officer, Myrtle Potter, Chief Executive Officer of Biopharma, Adele Gulfo, and Chief Medical Officer, Armin Szegedi, were appointed as Executive Officers of Sumitomo Pharma Co., Ltd. effective July 1, 2023. Innovation Growth Engine "We are pleased to have successfully completed the combination of Sumitomo Pharma's U.S. subsidiaries to form SMPA," said Hiroshi Nomura, Representative Director, President and Chief Executive Officer of Sumitomo Pharma. "As a Sumitomo Pharma Group growth engine, SMPA will focus on maximizing the value of the three key products early, namely, ORGOVYX®, MYFEMBREE®, and GEMTESA®. SMPA will propel scientific and therapeutic innovations to meaningfully impact the evolving health needs of patients in North America and promote development to meet the needs of patients worldwide while also delivering long-term value to society as a stronger, more profitable enterprise." "SMPA comprises some of the brightest talent in drug development, business, science, and technology, operating as one global team to push beyond industry norms and reimagine what's possible," said Myrtle Potter, President and Chief Executive Officer, Sumitomo Pharma America. "Our goal is to realize new treatments with greater benefit to patients while maximizing the potential of our key marketed and development assets to better support areas of critical need and provide potential treatment options where solutions are lacking or do not exist." Commercial Biopharma Business Adele Gulfo, Chief Executive Officer of Biopharma Commercial of Sumitomo Pharma America, said, "SMPA is poised to help solve health challenges in critical disease areas through the exceptional talents and dedication of our highly experienced cross-functional team. SMPA's broad product portfolio, including key brands, ORGOVYX®, MYFEMBREE® and GEMTESA®, will drive the growth of our business and fuel future potential investments. We are deeply committed to the patients we serve in oncology, women's health, urology, rare disease, psychiatry, and neurology, as well as our additional products APTIOM®, RETHYMIC®, and LATUDA®, which healthcare providers and patients continue to rely on." R&D & Pipeline Armin Szegedi, Chief Medical Officer of Sumitomo Pharma America, said, "SMPA has a robust and balanced pipeline, with more than 30 assets and dozens of clinical trials currently underway, to address areas of significant need in psychiatry, neurology, oncology, urology, and regenerative medicine. I am excited about the opportunities we have at SMPA to develop innovative treatments across multiple therapeutic indications, including our lead pipeline candidate, ulotaront, which is being studied in individuals living with schizophrenia, generalized anxiety disorder and the adjunctive treatment of major depressive disorder." Jatin Shah, Chief Oncology Development Officer of Sumitomo Pharma America, added, "SMPA is uniquely positioned with a strong internal discovery and translational research engine committed to the identification and development of innovative, best-in-class, oncology therapies. We are also looking forward to quickly advancing our oncology programs including, TP-3654, an investigational selective oral PIM1 kinase inhibitor, being studied for patients with myelofibrosis (MF) and DSP-5336, an investigational small molecule inhibitor against the binding of menin and mixed-lineage leukemia (MLL) protein, being evaluated for the treatment of acute myeloid leukemia (AML)." SMPA's leadership team comprises industry-leading experts with deep life sciences expertise across the business and drug development spectrum, as well as quality & manufacturing, commercialization, and data & analytics. We invite you to learn about SMPA's full leadership team and capabilities on our new website: . About Sumitomo Pharma America, Inc. Sumitomo Pharma America (SMPA) is focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry & neurology, oncology, urology, women's health, rare disease, and cell & gene therapies. The company's diverse portfolio includes several marketed products and a robust pipeline of early- to late-stage assets. SMPA leverages proprietary in-house advanced analytics and computational technology platforms to accelerate discovery, research, and help bring novel therapies to patients sooner. SMPA is a Sumitomo Pharma Co., Ltd., company. For more information on SMPA, visit our website or follow us on LinkedIn. About Sumitomo Pharma Co., Ltd. Sumitomo Pharma is among the top-ten listed pharmaceutical companies in Japan, operating globally in major pharmaceutical markets, including Japan, the U.S., China, and other Asian countries with more than 6,000 employees worldwide. Sumitomo Pharma defines its Mission as "To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide." Additional information about Sumitomo Pharma is available through its corporate website at . Forward-Looking Statements This press release contains forward-looking statements that may be deemed to be "forward-looking statements" within the meaning of applicable securities laws and Sumitomo Pharma America, Inc. may make related oral, forward-looking statements on or following the date hereof. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Forward-looking statements, by their nature, are subject to a variety of inherent risks and uncertainties that could cause actual results to differ materially from the results projected and reported results should not be considered as an indication of future performance. Many of these risks and uncertainties cannot be controlled by Sumitomo Pharma America, Inc. and you should not place undue reliance on any forward-looking statements. These forward-looking statements are based on information available to Sumitomo Pharma America, Inc. as of the date of this communication and speak only as of the date of this communication. Sumitomo Pharma America, Inc. does not assume any obligation to publicly update any forward-looking statements, except as may be required by law. No information contained on any website referenced in this press release is incorporated by reference herein. Sumitomo Pharma America, Inc. is a registered trademark of Sumitomo Pharma Co., Ltd. Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd. © 2023 Sumitomo Pharma America, Inc. All rights reserved. SMPA IR / Media Contact: Maya Frutiger VP, Head of Corporate Communications Sumitomo Pharma America, Inc. CorpComms@us.sumitomo-pharma.com View original content to download multimedia: SOURCE Sumitomo Pharma America, Inc.

Executive ChangePhase 3

20 Feb 2009

·www.pharmatimes.com

EMEA calls for Raptiva suspension, issues latest recommendations

On a busy day for the regulator, the European Medicines Agency has recommended that marketing authorisation be suspended for Merck KGaA/Genentech's psoriasis drug Raptiva over possible links between the drug and a rare but deadly brain infection. The EMEA’s Committee for Medicinal Products for Human Use (CHMP) said the benefits of Raptiva (efalizumab) no longer outweigh its risks, because of safety concerns, notably the occurrence of progressive multifocal leukoencephalopathy (PML) in patients taking the medicine. The CHMP noted three confirmed cases of PML in patients who had taken Raptiva for more than three years, two of resulted in the patient’s death, and the agency has received an additional report of a suspected case of PML, “which could not be confirmed”. Nevertheless, following a review, the CHMP has concluded that “Raptiva’s benefits are modest”. In addition to PML, Raptiva is associated with other serious side effects, including Guillain-Barre and Miller-Fisher syndromes, encephalitis, encephalopathy, meningitis, sepsis and opportunistic infections,” the EMEA noted. It added that “there is not enough evidence to identify a group of patients in which the benefits of Raptiva outweigh its risks”. The EMEA’s call for suspension came as its counterpart in the USA, the Food and Drug Administration, issued a public health advisory about the three confirmed reports of PML and the possible fourth case. The FDA stated that it will “take appropriate steps to ensure that the risks of Raptiva do not outweigh its benefits”. Merck, which markets Raptiva in Europe, said it would work with health authorities across the continent "to undertake all necessary measures to comply with the EMEA recommendations." Earlier this week, the Darmstadt-based group noted that it had written off 195 million euros due to “sharply lower sales expectations” for the drug. Staying with the EMEA, the agency has issued the latest list of positive opinions from the CHMP. The drugs recommended for approval include Wyeth’s Conbriza (bazedoxifene) for postmenopausal osteoporosis, Bial’s anti-epileptic Zebinix (eslicarbazepine; see story on today’s elert) and Fresenius’ Removab (catumaxomab) for the removal of cancerous fluid from the abdomen. The CHMP is also recommending approval for Nycomed’s over-the-counter versions of its own heartburn drug Pantozol (pantoprazole) and Teva’s generic version of Novartis’ anti-dementia drug Exelon (rivastigmine). However, it adopted a negative opinion for Biferonex (interferon-beta-1a), from Switzerland’s BioPartners, for multiple sclerosis. BioPartners is appealing the decsion, claiming that Biferonex demonstrated safety and efficacy profiles comparable to established interferon beta-1a products already on the market".

100 Deals associated with Eslicarbazepine Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D09612	Eslicarbazepine Acetate	N03AF04	DB09119

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Epilepsy	South Korea	Whan In Pharmaceutical Co., Ltd.	10 Nov 2020
Epilepsies, Partial	European Union	BIAL-Portela & Cia SA	21 Apr 2009
Epilepsies, Partial	Iceland	BIAL-Portela & Cia SA	21 Apr 2009
Epilepsies, Partial	Liechtenstein	BIAL-Portela & Cia SA	21 Apr 2009
Epilepsies, Partial	Norway	BIAL-Portela & Cia SA	21 Apr 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic peripheral neuropathic pain	Phase 3	Portugal	BIAL-Portela & Cia SA	01 Nov 2010
Neuralgia, Postherpetic	Phase 3	Germany	BIAL-Portela & Cia SA	01 Sep 2010
Epilepsy, Complex Partial	Phase 3	United States	BIAL-Portela & Cia SA	02 Dec 2008
Epilepsy, Complex Partial	Phase 3	United States	Sumitomo Pharma America, Inc.	02 Dec 2008
Epilepsy, Complex Partial	Phase 3	Argentina	BIAL-Portela & Cia SA	02 Dec 2008
Epilepsy, Complex Partial	Phase 3	Argentina	Sumitomo Pharma America, Inc.	02 Dec 2008
Epilepsy, Complex Partial	Phase 3	Belgium	BIAL-Portela & Cia SA	02 Dec 2008
Epilepsy, Complex Partial	Phase 3	Belgium	Sumitomo Pharma America, Inc.	02 Dec 2008
Epilepsy, Complex Partial	Phase 3	Brazil	Sumitomo Pharma America, Inc.	02 Dec 2008
Epilepsy, Complex Partial	Phase 3	Brazil	BIAL-Portela & Cia SA	02 Dec 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06597084 (CTgov)	Phase 2	Stroke \| Seizures \| Epilepsy ... View more	129	ESL 800 mg (Group A)	ffvfeohfbh = bcccymrmvt jwdvsmniyg (smuonsrwry, qcwhzygvtm - oqbbzifxsr) View more	-	02 May 2025
				Placebo (Group B)	ffvfeohfbh = wriyrnhlgz jwdvsmniyg (smuonsrwry, vcmixrqvxm - nurspyxvys) View more
IEC2023	Not Applicable	-	849	Eslicarbazepine Acetate	kbwbdszxkt(uvgthvigvo) = 43 reports rslemfhulo (sfehplbyrx ) View more	-	04 Sep 2023
AAN2023	Phase 3	Seizures	1,447	Eslicarbazepine Acetate 800mg	htsmmbidrb(yzxxgbaszy) = Incidence of AEs and AEs leading to discontinuation increased with ESL dose wafbsjjnhz (aanueqlsvq ) View more	Positive	25 Apr 2023
				Eslicarbazepine Acetate 1200mg
NCT02484001 (NCT01162460/NCT02484001; EudraCT 2009-011135-13/2015-001243-36, Pubmed \| Ther Adv Neurol Disord)	Phase 3	Seizures plasma lipid levels \| total cholesterol \| low-density lipoprotein (LDL) cholesterol	184	Eslicarbazepine acetate (ESL)	wbeukfrdbn(itepwtopmg) = tnlnlzjyev uxbpivbebu (mntsvsliyg ) View more	Positive	01 Jan 2023
				Controlled-release carbamazepine (CBZ-CR)	wbeukfrdbn(itepwtopmg) = ygnwvvysgx uxbpivbebu (mntsvsliyg ) View more
BIA-2093-208 \| BIA-2093-305 (EAN2022)	Phase 2/3	Seizures	-	Eslicarbazepine acetate	pvnfqqngcx(yjgyztalxi) = ikxerwhzlt ofyerirnjm (qwupxbtlsq ) View more	Positive	24 Jun 2022
				Placebo	pvnfqqngcx(yjgyztalxi) = nsivvievtq ofyerirnjm (qwupxbtlsq ) View more
BIA-2093-304 (EAN2021)	Not Applicable	-	496	Eslicarbazepine acetate 800mg/day	cswvytayec(ojupkplzxl) = 7.5% in Part II and not reported in Part III gngbwgeozj (oqcazjklex ) View more	Positive	18 Jun 2021
				Eslicarbazepine acetate 400-1600mg/day
NCT00957047 \| NCT00957684 \| NCT00988429 (Pubmed \| Epilepsy Res)	Phase 3	Epilepsies, Partial \| Seizures	-	eslicarbazepine acetate (Older adults (≥60 years))	ivcxszegmf(njfsavvpmi) = whsduotqzn lmsjznagjy (rynvcjumtn ) View more	-	01 Jan 2021
				eslicarbazepine acetate (Younger adults (18-59 years))	ivcxszegmf(njfsavvpmi) = sqsjjcnush lmsjznagjy (rynvcjumtn ) View more
NCT02484001 (Pubmed) Manual	Phase 3	Epilepsies, Partial	184	eslicarbazepine acetate (ESL/ESL)	zovmzjphvi(fbcmypydzg) = kycbnbqtch wcxvosbpxt (flcbxnavsb, 0.0292 - 0.1366) View more	Positive	01 Oct 2020
				controlled-release carbamazepine+eslicarbazepine acetate (CBZ-CR/ESL)	zovmzjphvi(fbcmypydzg) = ijjbfarbux wcxvosbpxt (flcbxnavsb, 0.0180 - 0.1210) View more
NCT03116828 (1585, CTgov)	Phase 4	Epilepsies, Partial	102	eslicarbazepine acetate (Eslicarbazepine Acetate (Arm 1))	hqdjlnyrbf = iysxhazdng fqaurqpihr (qqcocenwqm, kyyiramifd - cjbhlgyfcu)	-	16 Jun 2020
				eslicarbazepine acetate (Eslicarbazepine Acetate (Arm 2))	hqdjlnyrbf = nyhxbzpsur fqaurqpihr (qqcocenwqm, nfdocpvgcg - uqsdgbkina)
AAN2020	Not Applicable	Seizures	-	Eslicarbazepine Acetate 10-30 mg/kg/day	ikinvcavag(virriyssda) = mzgsxvybps kdhkuckfgv (eibcmgkqkt ) View more	-	14 Apr 2020
				Placebo	ikinvcavag(virriyssda) = cfdmjxzbps kdhkuckfgv (eibcmgkqkt ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis